Case of the Month

RSS | Login | Register

Case of the Month

Content coming soon

The "Case of the Month" is a clinical quiz focusing on diagnosing and managing treatment side effects, with a case description followed by discussion (500-1200 words).

Do you have a real-world experience that would make for an interesting "Case of the Month?" If so, please contact us at editor.ona@haymarketmedia.com.

In the meantime, please bookmark OncologyNurseAdvisor.com and visit back in the coming months as we launch our new publication in May 2010, and add more content to our Web site.

Two vital resources for melanoma management

Two myCME Webcasts, Management of Metastatic Melanoma and Management of Early Melanoma and Atypical Spitz Tumors, provide health care professionals with current and relevant research, treatment options, clinical data, guidance, and resources to optimize melanoma detection, management, patient care, and outcomes. Each Webcast offers 1.0 AMA PRA Category 1 Credit^TM.

ONA Newsletters

Issue Preview
Latest CE
Reflections
Editor's choice
New on the Web

Register Now

twitter.com/ONAcom

FEBRUARY 3 - 4
• 2012 Highlights of ASH in North America
New York, New York
• 2012 Highlights of ASH in North America
San Francisco, California

MARCH 3 - 4
• 2012 Highlights of ASH in Asia
Singapore, Singapore

MAY 3 - 6
• 37th Annual ONS Congress
New Orleans, Louisiana

Click here to view the full calendar

Subscribe to the RSS for this page [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

Delicia Honen Yard February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.

Experimental agent slows progression of colorectal cancer

Delicia Honen Yard February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.

In HER2 breast cancer, lapatinib works better with trastuzumab than without

Delicia Honen Yard February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.